EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US

Mirre Scholte iD, Liam Bendicksen iD, Sabine E Grimm, Teebah Abu-Zahra, Bianca Pauly, Manuela Joore, Aaron S Kesselheim

Journal of Law, Medicine & Ethics · 2024 · 52 (4) · 940-949

DOI: 10.1017/jme.2024.171 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Law, Medicine & Ethics, online erschienen am 31.01.2025. Verfasst von Mirre Scholte und 6 weiteren Autor:innen. Beteiligte Einrichtung: DEPARTMENT OF CLINICAL EPIDEMIOLOGY & MEDICAL TECHNOLOGY ASSESSMENT (KEMTA), MAASTRICHT UNIVERSITY MEDICAL CENTRE, MAASTRICHT, THE NETHERLANDS. Hauptthemen laut MEDLINE: Drug Repositioning, Drug Approval, United States Food and Drug Administration, European Union. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Health and Digital Executive Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To help academic and non-profit investigators interested in drug repurposing navigate regulatory approval processes, we compared pathways for repurposed drugs to obtain approval at EMA, UK MHRA, and the US FDA. Though we found no pathways specifically for repurposed drugs, pathways to market are available in all repurposing scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningDrug ApprovalUnited States Food and Drug AdministrationEuropean UnionUnited StatesHumansUnited Kingdom

Stichwörter der Autor:innen

Drug ApprovalsDrug RepurposingEuropean Medicines AgencyPrescription Drug RegulationUK Medicines and Healthcare Products Regulatory AgencyUS Food and Drug Administration

Autor:innen und Institutionen

  • DEPARTMENT OF CLINICAL EPIDEMIOLOGY & MEDICAL TECHNOLOGY ASSESSMENT (KEMTA), MAASTRICHT UNIVERSITY MEDICAL CENTRE, MAASTRICHT, THE NETHERLANDS.
  • CARE AND PUBLIC HEALTH RESEARCH INSTITUTE (CAPHRI), MAASTRICHT UNIVERSITY, MAASTRICHT, THE NETHERLANDS.
  • DEPARTMENTS OF IQ HEALTH & RADIOLOGY, RADBOUDUMC, NIJMEGEN, THE NETHERLANDS.
  • PROGRAM ON REGULATION, THERAPEUTICS, AND LAW (PORTAL), DIVISION OF PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS, DEPARTMENT OF MEDICINE, BRIGHAM & WOMEN'S HOSPITAL/HARVARD MEDICAL SCHOOL, BOSTON, MASSACHUSETTS, USA.
  • REGULATORY AFFAIRS DEPARTMENT, 3D-PHARMXCHANGE, TILBURG, THE NETHERLANDS.

ORCID-Profile: Mirre Scholte, Liam Bendicksen

Förderung

  • European Health and Digital Executive Agency

Zitieren

APA

Scholte, M., Bendicksen, L., Grimm, S. E., Abu-Zahra, T., Pauly, B., Joore, M., & Kesselheim, A. S. (2024). A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US. Journal of Law, Medicine & Ethics, 52(4), 940-949. https://doi.org/10.1017/jme.2024.171

Vancouver

Scholte M, Bendicksen L, Grimm SE, Abu-Zahra T, Pauly B, Joore M, et al. A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US. Journal of Law, Medicine & Ethics. 2024;52(4):940-949. doi:10.1017/jme.2024.171

BibTeX
@article{Scholte2024,
  author = {Scholte, Mirre and Bendicksen, Liam and Grimm, Sabine E and Abu-Zahra, Teebah and Pauly, Bianca and Joore, Manuela and Kesselheim, Aaron S},
  title = {A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US},
  journal = {Journal of Law, Medicine & Ethics},
  year = {2024},
  volume = {52},
  number = {4},
  pages = {940--949},
  doi = {10.1017/jme.2024.171}
}
Kostenlos starten →